Taro Pharmaceutical Industries Ltd. (TARO) |
| 42.975 0.005 (0.01%) 06-21 15:59 |
| Open: | 42.97 |
| High: | 42.98 |
| Low: | 42.94 |
| Volume: | 147,064 |
| Market Cap: | 1,615(M) |
| PE Ratio: | 30.05 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 76.25 |
| Resistance 1: | 70.47 |
| Pivot price: | 66.50 |
| Support 1: | 61.13 |
| Support 2: | 50.86 |
| 52w High: | 45.76 |
| 52w Low: | 32.67 |
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
| EPS | 1.840 |
| Book Value | 400.000 |
| PEG Ratio | 1.45 |
| Gross Profit | 243608000.000 |
| Profit Margin (%) | 8.40 |
| Operating Margin (%) | 14.80 |
| Return on Assets (ttm) | 11.2 |
| Return on Equity (ttm) | 33.7 |
Mon, 05 Oct 2026
$200M Sun, Taro generic drug antitrust class action settlement - Top Class Actions
Thu, 24 Sep 2026
Taro Pharmaceutical Industries stock faces a legal settlement - ad-hoc-news.de
Thu, 24 Sep 2026
Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System - PR Newswire Canada
Sat, 12 Sep 2026
Sun Pharma Subsidiaries Settle with Plaintiff in US Generic Drug Pricing Litigation - Medical Dialogues
Fri, 11 Sep 2026
News by CNBC TV18 on TradingView, 2026-09-11 — cnbctv:df10e080b094b:0 - TradingView
Thu, 27 Aug 2026
Taro Pharmaceutical Industries Ltd. - ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |